Murine Models in the Evaluation of Heparan Sulfate-Based Anticoagulants.
Anticoagulant
Arterial thrombosis
Heparin
Mouse
Saphenous vein bleeding time
Tail bleeding time
Venous thrombosis
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
9
10
2021
pubmed:
10
10
2021
medline:
12
1
2022
Statut:
ppublish
Résumé
Evaluating prospective anticoagulant therapies in animal thrombosis and bleeding models are standard pre-clinical approaches. Mice are frequently used for initial evaluations because a variety of models have been developed in this well-characterized species, and mice are relatively inexpensive to maintain. Because mice seem to be resistant to forming "spontaneous" thrombosis, vessel injury is used to induce intravascular clot formation. For the purpose of testing heparin-based drugs, we adapted a well-established model in which thrombus formation in the carotid artery is induced by exposing the vessel to ferric chloride. For studying anticoagulant effects on venous thrombosis, we use a model in which the inferior vena cava is ligated and the size of the resulting clots are measured. The most common adverse effect of anticoagulation therapy is bleeding. We describe a simple tail bleeding time that has been used for many years to study the effects of anticoagulants on hemostasis. We also describe a more reproducible, but more technically challenging, saphenous vein bleeding model that is also used for this purpose.
Identifiants
pubmed: 34626423
doi: 10.1007/978-1-0716-1398-6_59
pmc: PMC8552346
mid: NIHMS1748253
doi:
Substances chimiques
Anticoagulants
0
Heparitin Sulfate
9050-30-0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
789-805Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL058837
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL081326
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL140025
Pays : United States
Informations de copyright
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Day SM, Reeve JL, Myers DD, Fay WP (2004) Murine thrombosis models. Thromb Haemost 92:486–494
pubmed: 15351844
doi: 10.1055/s-0037-1613739
Westrick RJ, Winn ME, Eitzman DT (2007) Murine models of vascular thrombosis. Arterioscler Thromb Vasc Biol 27:2079–2093
pubmed: 17600224
doi: 10.1161/ATVBAHA.107.142810
Sachs UJ, Nieswandt B (2007) In vivo thrombus formation in murine models. Circ Res 100:979–991
pubmed: 17431199
doi: 10.1161/01.RES.0000261936.85776.5f
Furie B (2009) Pathogenesis of thrombosis. Hematology 2009:255–258
doi: 10.1182/asheducation-2009.1.255
Diaz JA, Obi AT, Myers DD Jr, Wrobleski SK, Henke PK, Mackman N, Wakefield TW (2012) Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol 32:556–562
pubmed: 22345593
pmcid: 3292052
doi: 10.1161/ATVBAHA.111.244608
Albadawi H, Witting AA, Pershad Y, Wallace A, Fleck AR, Hoang P, Khademhosseini A, Oklu R (2017) Animal models of venous thrombosis. Cardiovasc Diagn Ther 7(Suppl 3):S197–S206
pubmed: 29399523
pmcid: 5778525
doi: 10.21037/cdt.2017.08.10
Diaz JA, Saha P, Cooley B, Palmer OR, Grover SP, Mackman N, Wakefield TW, Henke PK, Smith A, Lal BK (2019) Choosing a mouse model of venous thrombosis: a consensus assessment of utility and application. J Thromb Haemost 17:699–707
pubmed: 30927321
doi: 10.1111/jth.14413
Posma JJ, Grover SP, Hisada Y, Owensill AP, Antoniak S, Spronk HM, Mackman N (2019) Roles of coagulation proteases and PARs (protease-activated receptors) in mouse models of inflammatory disease. Arterioscler Thromb Vasc Biol 39:13–24
pubmed: 30580574
pmcid: 6310042
doi: 10.1161/ATVBAHA.118.311655
Mohammed BM, Monroe DM, Gailani D (2020) Mouse models of hemostasis. Platelets 31:417–422
pubmed: 31992118
pmcid: 7244364
doi: 10.1080/09537104.2020.1719056
Hogan KA, Weiler H, Lord ST (2002) Mouse models of coagulation. Thromb Haemost 87:563–574
pubmed: 12008936
doi: 10.1055/s-0037-1613050
Emeis JJ, Jirouskova M, Muchitsch EM, Shet AS, Smyth SS, Johnson GJ (2007) A guide to murine coagulation factor structure, function, assays, and genetic alterations. J Thromb Haemost 5:670–679
pubmed: 17403201
doi: 10.1111/j.1538-7836.2007.02408.x
McManus MP, Gailani D (2012) Mouse models of coagulation factor deficiencies. In: Animal models of diseases: translational medicine perspective for drug discovery and development. Bentham Scientific Publishers, pp 67–121
Brake MA, Ivanciu L, Maroney SA, Martinez ND, Mast AE, Westrick RJ (2019) Assessing blood clotting and coagulation factors in mice. Curr Protoc Mouse Biol 9(2):e61
pubmed: 30875463
pmcid: 6771260
doi: 10.1002/cpmo.61
Rezaie AR, Giri H (2020) Antithrombin: an anticoagulant, anti-inflammatory and antibacterial serpin. J Thromb Haemost 18:528–533
pubmed: 32112532
pmcid: 7080319
doi: 10.1111/jth.14724
Tollefsen DM, Zhang L (2013) Heparin and vascular proteoglycans. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC (eds) Hemostasis and thrombosis, basic principles and clinical practice, 6th edition. Lippincott. Williams and Wilkins, Philadelphia, pp 585–597
Buyue Y, Misenheimer TM, Sheehan JP (2012) Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism. J Thromb Haemost 10:2086–2098
pubmed: 22905983
pmcid: 3463736
doi: 10.1111/j.1538-7836.2012.04892.x
Kung SH, Hagstrom JN, Cass D, Tai SJ, Lin HF, Stafford DW, High KA (1998) Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood 91:784–790
pubmed: 9446637
doi: 10.1182/blood.V91.3.784
Geng Y, Verhamme IM, Smith SB, Sun MF, Matafonov A, Cheng Q, Smith SA, Morrissey JH, Gailani D (2013) The dimeric structure of factor XI and zymogen activation. Blood 121:3962–3969
pubmed: 23515926
pmcid: 3650707
doi: 10.1182/blood-2012-12-473629
Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B (2005) Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 202:271–281
pubmed: 16009717
pmcid: 2213000
doi: 10.1084/jem.20050664
Ivanov I, Matafonov A, Sun MF, Cheng Q, Dickeson SK, Verhamme IM, Emsley J, Gailani D (2017) Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation. Blood 129:1527–1537
pubmed: 28069606
pmcid: 5356457
doi: 10.1182/blood-2016-10-744110
Carcao M, Moorehead P, Lillicrap D (2018) Hemophilia A and B. In: Hoffman RH, Benz EJ, Silberstein LE, Heslop H, Weitz JI, Anastasi J, Salama ME, Abutalib SA (eds) Hematology, basic principles and practice, 7th edn. Saunders-Elsevier, Philadelphia, pp 2001–2022
Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW (1997) A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 90:3962–3966
pubmed: 9354664
doi: 10.1182/blood.V90.10.3962
Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, Kooistra T (2007) Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27:1706–1721
pubmed: 17541027
doi: 10.1161/ATVBAHA.107.142570
Lee YT, Lin HY, Chan YWF, Li KHC, To OTL, Pan BY, Liu T, Li G, Wong WT, Keung W, Tse G (2017) Mouse models of atheroscerlosis: a historical perspective and recent advances. Lipids Health Dis 16:12
pubmed: 28095860
pmcid: 5240327
doi: 10.1186/s12944-016-0402-5
Oppi S, Luscher TF, Stein S (2019) Mouse models for atherosclerosis research – which is my line. Cardiovasc Med 6:46
Zhang SH, Reddick RL, Burkey B, Maeda N (1994) Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest 94:937–945
pubmed: 8083379
pmcid: 295131
doi: 10.1172/JCI117460
Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R (1994) ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb Vasc Biol 14:133–140
doi: 10.1161/01.ATV.14.1.133
Siegal D, Lim W (2018) Venous thromboembolism. In: Hoffman RH, Benz EJ, Silberstein LE, Weitz HH, JI AJ, Salama ME, Abutalib SA (eds) Hematology, basic principles and practice, 7th edn. Saunders-Elsevier, Philadelphia, pp 2102–2112
Eckly A, Hechler B, Freund M, Zerr M, Cazenave JP, Lanza F, Mangin PH, Gachet C (2011) Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemost 9:779–789
pubmed: 21261806
doi: 10.1111/j.1538-7836.2011.04218.x
Owens AP 3rd, Lu Y, Whinna HC, Gachet C, Fay WP, Mackman N (2011) Towards a standardization of the murine ferric chloride-induced carotid arterial thrombosis model. J Thromb Haemost 9:1862–1863
pubmed: 21884567
doi: 10.1111/j.1538-7836.2011.04287.x
Barr JD, Chauhan AK, Schaeffer GV, Hansen JK, Motto DG (2013) Red blood cells mediate the onset of thrombosis in the ferric chloride murine model. Blood 121:3733–3741
pubmed: 23343833
pmcid: 3643770
doi: 10.1182/blood-2012-11-468983
Wang X, Xu L (2005) An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thromb Res 115:95–100
pubmed: 15567459
doi: 10.1016/j.thromres.2004.07.009
Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, Seiffert DA, Schumacher WA, Ogletree ML, Gailani D (2005) Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 3:695–702
pubmed: 15733058
doi: 10.1111/j.1538-7836.2005.01236.x
Gailani D, Gruber A (2016) Factor XI as a therapeutic target. Arterioscler Thromb Vasc Biol 36:1316–1322
pubmed: 27174099
pmcid: 4919154
doi: 10.1161/ATVBAHA.116.306925
Al-Horani RA, Gailani D, Desai UR (2015) Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants. Thromb Res 136:379–387
pubmed: 25935648
pmcid: 4526391
doi: 10.1016/j.thromres.2015.04.017
Mehta AY, Mohammed BM, Martin EJ, Brophy DF, Gailani D, Desai UR (2016) Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin. J Thromb Haemost 14:828–838
pubmed: 26748875
pmcid: 4828251
doi: 10.1111/jth.13254
Wang L, Miller C, Swarthout RF, Rao M, Mackman N, Taubman MB (2009) Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury. Blood 113:705–713
pubmed: 18931346
pmcid: 2628377
doi: 10.1182/blood-2007-05-090944
Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, White-Adams TC, Smith SA, Hanson SR, McCarty OJ, Renné T, Gruber A, Gailani D (2010) A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 116:3981–3989
pubmed: 20634381
pmcid: 2981546
doi: 10.1182/blood-2010-02-270918
Wang X, Smith PL, Hsu MY, Gailani D, Schumacher WA, Ogletree ML, Seiffert DA (2006) Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost 4:1982–1988
pubmed: 16961605
doi: 10.1111/j.1538-7836.2006.02093.x
Revenko AS, Gao D, Crosby JR, Bhattacharjee G, Zhao C, May C, Gailani D, Monia BP, MacLeod AR (2011) Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 118:5302–5311
pubmed: 21821705
pmcid: 4425441
doi: 10.1182/blood-2011-05-355248
Jaffer IH, Weitz JI (2018) Antithrombotic drugs. In: Hoffman RH, Benz EJ, Silberstein LE, Weitz HH, JI A, J Salama ME, Abutalib SA (eds) Hematology, basic principles and practice, 7th edn. Saunders-Elsevier, Philadelphia, pp 2168–2188
Weitz JI, Chan NC (2020) Novel antithrombotic strategies for treatment of venous thromboembolism. Blood 135:351–359
pubmed: 31917385
doi: 10.1182/blood.2019000919
Al-Horani RA (2020) Targeting factor XI(a) for anticoagulation therapy: a patent landscape. Pharm Pat Anal 9:3–5
pubmed: 32057285
doi: 10.4155/ppa-2020-0002
Srivastava P, Gailani D (2020) Rebirth of the contact pathway: a new therapeutic target. Curr Opin Hematol 27:311–319
pubmed: 32740037
pmcid: 7596882
doi: 10.1097/MOH.0000000000000603
Greene TK, Schiviz A, Hoellriegl W, Poncz M, Muchitsch EM (2010) Animal models Subcommittee of the Scientific and Standardization Committee of the Isth. Towards a standardization of the murine tail bleeding model. J Thromb Haemost 8:2820–2822
pubmed: 21138523
doi: 10.1111/j.1538-7836.2010.04084.x
Liu Y, Jennings NL, Dart AM, Du X-J (2012) Standardizing a simpler, more sensitive and accurate tail bleeding assay in mice. World J Exp Med 2:30–36
pubmed: 24520531
pmcid: 3905578
doi: 10.5493/wjem.v2.i2.30
Broze GJ Jr, Yin ZF, Lasky N (2001) A tail vein bleeding time model and delayed bleeding in hemophiliac mice. Thromb Haemost 85:747–748
pubmed: 11341518
doi: 10.1055/s-0037-1615666
Molina ES, Fujita A, Sogayar MC, Demasi MA (2014) A quantitative and humane tail bleeding assay for efficacy evaluation of antihaemophilic factors in haemophilia A mice. Haemophilia 20:e392–e398
pubmed: 24975823
doi: 10.1111/hae.12484
Saito MS, Lourenço AL, Kang HC, Rodrigues CR, Cabral LM, Castro HC, Satlher PC (2016) New approaches in tail-bleeding assay in mice: improving an important method for designing new anti-thrombotic agents. Int J Ex Pathol 97:285–292
doi: 10.1111/iep.12182
Buyue Y, Whinna HC, Sheehan JP (2008) The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis. Blood 112:3234–3241
pubmed: 18647957
pmcid: 2569175
doi: 10.1182/blood-2008-01-136820
Pastoft AE, Lykkesfeldt J, Ezban M, Tranholm M, Whinna HC, Lauritzen B (2012) A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate). Haemophilia 18:782–788
pubmed: 22500820
doi: 10.1111/j.1365-2516.2012.02780.x
Feng D, Whinna H, Monroe D, Stafford DW (2014) FVIIa as used pharmacologically is not TF dependent in hemophilia B mice. Blood 123:1764–1766
pubmed: 24425804
pmcid: 3954056
doi: 10.1182/blood-2013-08-522987
Monroe DM, Hoffman M (2014) A mouse bleeding model to study oral anticoagulants. Thromb Res 133(Suppl 1):S6–S8
pubmed: 24759147
pmcid: 4014069
doi: 10.1016/j.thromres.2014.03.003